Leerink Partners Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $12
Aquestive Therapeutics: A Buy Rating on Revolutionary Allergy Treatments and Strategic Pipeline Expansion
Hedge Funds Pile Into Healthcare Stocks Amid Dip, Goldman Sachs Says
Analysts Offer Insights on Healthcare Companies: Acadia Healthcare (ACHC), Aquestive Therapeutics (AQST) and Inspire Medical Systems (INSP)
Optimism Around Aquestive As It Moves Forward With Severe Allergy, Baldness Candidate
Aquestive Therapeutics Shares Are Trading Higher After HC Wainwright & Co and Leerink Partners Raised Their Respective Price Targets on the Stock.